Bioengineering: alpha 1-proteinase inhibitor site-specific mutagenesis. The prospect for improving the inhibitor.

doi:10.1378/chest.110.6_supplement.278s

Back to search

Article

Bioengineering: alpha 1-proteinase inhibitor site-specific mutagenesis. The prospect for improving the inhibitor.

Chest - 1 Dec 1996

Luisetti M, Travis J

Abstract excerpt

alpha 1-Proteinase inhibitor (alpha 1-PI) augmentation therapy has been licensed for treatment of alpha 1-PI-deficient individuals with pulmonary emphysema. The currently available product is purified from pooled human plasma. To obtain larger amounts of protein free from possible unknown plasma...

Topics

Humans
Leukocyte Elastase
Mutagenesis, Site-Directed
Neutrophils
Phenotype
Pulmonary Emphysema
Recombinant Proteins
Smoking
alpha 1-Antitrypsin
alpha 1-Antitrypsin Deficiency

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.